BofA Securities Reiterates Underperform Rating on Myriad Genetics (MYGN), Sees Guidance as a Stretch
Tweet Send to a Friend
BofA Securities analyst Derik de Bruin reiterated an Underperform rating and $27.00 price target on Myriad Genetics (NASDAQ: MYGN) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
